Ehrenfeld M. Spondyloarthropathies. Best Pract Res Clin Rheumatol. 2012;26:135–45.

Article  CAS  PubMed  Google Scholar 

Khan MA. Update on spondyloarthropathies. Ann Intern Med. 2002;136:896–907.

Article  PubMed  Google Scholar 

Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford). 2019;58:i43–54.

Article  CAS  PubMed  Google Scholar 

Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18:133–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adas MA, Alveyn E, Cook E, Dey M, Galloway JB, Bechman K. The infection risks of JAK inhibition. Expert Rev Clin Immunol. 2022;18:253–61.

Article  CAS  PubMed  Google Scholar 

Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316–26.

Article  CAS  PubMed  Google Scholar 

Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, Landewe RBM, Van den Bosch FE, Boteva B, Bremander A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82:19–34.

Article  PubMed  Google Scholar 

Kragstrup TW, Glintborg B, Svensson AL, McMaster C, Robinson PC, Deleuran B, Liew DF. Waiting for JAK inhibitor safety data. RMD Open. 2022;8: e002236.

Article  PubMed  PubMed Central  Google Scholar 

Mease PJ, Lertratanakul A, Anderson JK, Papp K, Van den Bosch F, Tsuji S, Dokoupilova E, Keiserman M, Wang X, Zhong S, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021;80:312–20.

Article  CAS  PubMed  Google Scholar 

McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M, Jeka S, Pacheco-Tena C, Wang X, Chen L, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384:1227–39.

Article  CAS  PubMed  Google Scholar 

van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Everding A, Sui Y, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019;394:2108–17.

Article  PubMed  Google Scholar 

van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, Zeng X, Sui Y, Bu X, Pangan AL, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022;81:1515–23.

Article  PubMed  Google Scholar 

Deodhar A, Van den Bosch F, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, Kishimoto M, Blanco R, Duan Y, Li Y, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400:369–79.

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration. Highlights of prescribing information [upadacitinib]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211675s012lbl.pdf. Accessed 22 April 2024.

Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, et al. Safety profile of upadacitinib over 15000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9: e002735.

Article  PubMed  PubMed Central  Google Scholar 

Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L, Zhang Y, Khan N, Hendrickson B, Enejosa JV, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2020;80(3):304–11.

Article  PubMed  Google Scholar 

Navarro-Compan V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021;80:1511–21.

Article  CAS  PubMed  Google Scholar 

Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis. 2011;70(Suppl 1):i77–84.

Article  PubMed  Google Scholar 

Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewe R, Mease P, Sieper J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77:3–17.

Article  PubMed  Google Scholar 

Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71:1285–99.

Article  PubMed  Google Scholar 

Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13:320.

Article  PubMed  Google Scholar 

Winthrop KL, Tanaka Y, Lee EB, Wollenhaupt J, Al Enizi A, Azevedo VF, Curtis JR. Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review. Clin Exp Rheumatol. 2022;40:162–72.

Article  PubMed  Google Scholar 

Venkat R, Wallace ZS, Sparks JA. Considerations for pharmacologic management of rheumatoid arthritis in the COVID-19 era: a narrative review. Curr Rheumatol Rep. 2023;25(11):236–45.

Article  PubMed  Google Scholar 

Curtis JR, Zhou X, Rubin DT, Reinisch W, Yazdany J, Robinson PC, Chen Y, Benda B, Madsen A, Geier J. Characteristics, comorbidities, and outcomes of SARS-CoV-2 infection in patients with autoimmune conditions treated with systemic therapies: a population-based study. J Rheumatol. 2022;49:320–9.

Article  CAS  PubMed  Google Scholar 

Sobczak M, Pawliczak R. COVID-19 mortality rate determinants in selected Eastern European countries. BMC Public Health. 2022;22:2088.

Article  PubMed  PubMed Central  Google Scholar 

Ye Y, Yue X, Krueger WS, Wegrzyn LR, Maniccia AW, Winthrop KL, Kim SC. Factors associated with severe COVID-19 among patients with rheumatoid arthritis: a large, nationwide electronic health record cohort study in the United States. Adv Ther. 2023;40:3723–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tran AP, Tassone DF, Ding NS, Nossent J. Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2). RMD Open. 2023;9: e002871.

Article  PubMed  Google Scholar 

Liu R, Wan Q, Zhao R, Xiao H, Cen Y, Xu X. Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis. Cancer Cell Int. 2021;21:614.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jalles C, Lepelley M, Mouret S, Charles J, Leccia MT, Trabelsi S. Skin cancers under Janus kinase inhibitors: a World Health Organization drug safety database analysis. Therapie. 2022;77:649–56.

Article  PubMed  Google Scholar 

Charles-Schoeman C, Choy E, McInnes IB, Mysler E, Nash P, Yamaoka K, Lippe R, Khan N, Shmagel AK, Palac H, et al. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023;9: e003392.

Article  PubMed  PubMed Central  Google Scholar